Loading...
Loading...
Browse all stories on DeepNewz
VisitRelay Therapeutics' RLY-2608 Shows Positive Interim Data, Stock Rises 21.2%
Sep 9, 2024, 11:15 AM
Relay Therapeutics announced on Monday positive interim data for its experimental treatment, RLY-2608, which demonstrates clinically meaningful progression-free survival in patients with HR+/HER2- breast cancer. The early-stage study indicates that the combination treatment significantly extended the time patients lived without their disease worsening. Following the announcement, Relay Therapeutics' stock (RLAY) saw a pre-market increase of 21.2%. Dr. Don Bergstrom, President of R&D at Relay Therapeutics, highlighted the significance of these findings.
View original story
Markets
No • 50%
Yes • 50%
Official press releases from Relay Therapeutics or reputable news sources
Yes • 50%
No • 50%
Stock market data from reputable financial news sources like Bloomberg or Yahoo Finance
No • 50%
Yes • 50%
FDA announcements and Relay Therapeutics' official press releases
Top 30 • 25%
Top 10 • 25%
Below Top 30 • 25%
Top 20 • 25%
Financial market data from reputable sources like Bloomberg or Yahoo Finance
No results announced • 25%
Mixed results • 25%
Positive results • 25%
Negative results • 25%
Official press releases from Relay Therapeutics and clinical trial registries
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Stock market data from reputable financial news sources like Bloomberg or Yahoo Finance